Real World Psilocybin Outcomes

States

This dashboard shows aggregate, real-world outcomes from licensed psilocybin services at healing centers in Oregon and Colorado, updated in real time as facilitators and centers record sessions. All figures are aggregated across participants; no individual-level data is shown. See Methods & data notes for how this data is collected and what it can and cannot show.

Showing real-world data from January 2025 through August 2026.

Baseline Screening Scores

Wellness (WHO-5) Mean

13.2/ 25

n=3247

Anxiety (GAD-7) Mean

12.2/ 21

n=1072

Depression (PHQ-9) Mean

14.0/ 27

n=830

Wellness (WHO-5) CHANGE

+2.9

n=1180

13.5 → 16.4

Anxiety (GAD-7) CHANGE

-6.5

n=347

12.1 → 5.6

Depression (PHQ-9) CHANGE

-7.1

n=273

13.7 → 6.6

Wellness (WHO-5): Pre vs Post

n = 1180 paired scores

Baseline
2-Week Post

Anxiety (GAD-7): Pre vs Post

n = 347 paired scores

Baseline
2-Week Post

Depression (PHQ-9): Pre vs Post

n = 273 paired scores

Baseline
2-Week Post

Pre-post comparisons use strict pairing: only participants with both a baseline and two-week post-journey score for the same instrument are included. GAD-7 and PHQ-9 are administered adaptively — they only appear when initial screening scores (GAD-2 ≥ 3 or PHQ-2 ≥ 3) indicate elevated symptoms, so fewer participants have paired scores for these instruments.

Mystical Experiences (MEQ-30)

MEQ-30 Mean Total

100.7/ 150

n=2434

Complete Mystical Experience Rate

67.3%

n=2434

1639 scored >= 90

Adverse Events

Category	Timing	Adverse Events	Sessions Reported	Rate
Behavioral	During Session	35	4305	0.8%
Medical	During Session	44	4310	1.0%
Behavioral	Post Session	8	1578	0.5%
Medical	Post Session	14	1579	0.9%